PAVmed

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. Its products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. The company was founded on June 26, 2014 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. It operates through the following divisions: Medical Devices, Diagnostics, Digital Health, and Emerging Innovations. The company's products include cell collection devices, esophageal DNA tests, carpal tunnel release, implantable intraosseous vascular access devices, and antimicrobial resorbable ear tubes. PAVmed was founded on June 26, 2014 and is headquartered in New York, NY.

NEW YORK--(BUSINESS WIRE)---- $PAVM #earnings--PAVmed provides business update and preliminary fourth quarter and full year 2021 financial results.

PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results

PAVmed Inc (NASDAQ: PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients. No complications have occurred.

PAVmed Highlights First-In-Human Implantations of its PortIO Infusion System

NEW YORK--(BUSINESS WIRE)---- $PAVM #PortIO--PAVmed announces successful first-in-human implantations of its PortIO™ Intraosseous Infusion System.

PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System

NEW YORK--(BUSINESS WIRE)---- $PAVM #DigitalHealth--PAVmed subsidiary Veris Health launches world-class technology advisory board.

PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board

NEW YORK--(BUSINESS WIRE)---- $PAVM #Healthcare--PAVmed to hold a business update conference call on March 29, 2022.

PAVmed to Hold a Business Update Conference Call on March 29, 2022

The shares of the company are extremely volatile as visibility into the financial future of the company is limited. However, we do think that, while certainly not devoid of risk, the shares potentially contain much more value, given Lucid's addressable market and the rapid build-up of its commercial infrastructure.

Start Accumulating PAVmed

News of a fresh round of capital raising seems to be making some investors ill.

Why PAVmed Stock Plummeted on Wednesday

The stock price of PAVmed Inc (NASDAQ: PAVM) fell by over 10% pre-market today. This is why it happened.

PAVmed (PAVM) Stock: Why The Price Fell Today

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q3 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $PAVM--Veris Health showcased in PAVmed Digital Health Virtual Investor Event.

Veris Health Showcased in PAVmed Digital Health Virtual Investor Event

NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed Digital Health Subsidiary Veris Health appoints Sunny Webb as Chief Technology Officer.

PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer

Today, a relatively disappointing start to trading for a PAVmed subsidiary, Lucid Diagnostics, is driving some bearish price action. The post PAVM Stock: One Big Reason Why PAVmed Is Plunging Today appeared first on InvestorPlace.

PAVM Stock: One Big Reason Why PAVmed Is Plunging Today

Lucid Diagnostics

NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics announces pricing of Initial Public Offering.

Lucid Diagnostics Announces Pricing of Initial Public Offering

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed acquires EsophaCap manufacturer CapNostics LLC.

PAVmed Acquires EsophaCap Manufacturer CapNostics LLC

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed to Host Digital Health Virtual Investor Event, Veris Health: Bringing Digital Health to Cancer Care.

PAVmed to Host Digital Health Virtual Investor Event

PAVmed Inc (NASDAQ: PAVM) is trading higher Thursday after the company announced its majority-owned subsidiary, Lucid Diagnostics, filed a registration statement for a proposed initial public offering. The number of shares to be offered and the price range for the offering have not yet been determined.

Why PAVmed Shares Are Trading Higher Today

Veritone

In a rising market, these companies looked especially impressive.

These 2 Nasdaq Small Caps Just Got Big Boosts

The stock price of PAVmed Inc (NASDAQ: PAVM) increased over 20% in the past 5 trading days. This is why it happened.

PAVM Stock: Why It Substantially Increased This Past Week

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary, Lucid Diagnostics, files registration statement for proposed initial public offering.

PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Veris Health joins Microsoft for startups global program and engages Loka as software development partner.

PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development Partner

NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed to participate in September investor and MedTech conferences.

PAVmed to Participate in September Investor and MedTech Conferences

EsoGuard/EsoCheck showed pretty slow growth in Q2 but momentum should improve as the company starts targeting consumers and PCPs directly and launches into Europe. Momentum for PAVM's pipeline products remains strong, and the company remains on track to get 3-4 products on the market by the end of 2022.

PAVmed: Long Term Investment Case Remains Despite Weak Q2

Investors are growing impatient about a planned spinoff.

Why Shares of PAVmed Were Down This Morning

PAVmed Inc. (PAVM) CEO Lishan Aklog on Q2 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results. Conference call to be held today at 4:30 PM EDT.

News for PAVmed Stock (PAVM)